This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Stock Winners and Losers: Glaxo

Updated from 3:16 p.m. EDT

Buoyed by the idea that swine flu fears could at least temporarily boost sales at some firms, health care stocks were largely in the green Monday.

GlaxoSmithKline (GSK - Get Report), which makes antiviral drug Relenza, was among the day's early winners. The company, which issued a press release Monday that said it had sent Mexican officials 100,000 packs of Relenza and 170,000 additional doses of its seasonal flu vaccine, is "urgently assessing" ways to increase production of Relenza. Shares of the company rose 7.6% to $31.56. Novavax (NVAX - Get Report), which owns technology for creating vaccines, rose 79.6% to $2.55.

Swine Flu Outbreak

Pfizer (PFE - Get Report) shares rose 2.4% to $13.49 a day before the company's quarterly earnings report. Analysts expect the Lipitor maker, which is buying Wyeth (WYE), to report earnings of 49 cents on $11.08 billion in revenue, according to Thomson One.

Bristol-Myers Squibb (BMY - Get Report), which also reports earnings Tuesday, rose 2.2% to $20.54. Analysts polled by Thomson One expect the firm to earn 47 cents per share on $5.13 billion in revenue.


Eli Lilly (LLY) shares rose 0.4% to $33.13.

Johnson & Johnson (JNJ - Get Report) fell 0.1% to $50.86.

Merck (MRK) was essentially flat at $23.44.

Novo Nordisk (NVO - Get Report) fell 2.6% to $47.49. The company reports earnings Thursday.

Abbott Labs (ABT - Get Report) rose 0.2% to $43.16.

Schering-Plough (SGP) rose 0.1% to $22.19.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ABT $46.50 0.00%
BMY $65.00 0.00%
GSK $46.66 0.00%
JNJ $100.12 -0.02%
NVAX $7.58 0.00%


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs